Global Head & Neck Squamous Cell Carcinoma Market Report 2016-2024 - Analysis, Technologies & Forecasts - Key Vendors: Amgen, Pfizer, Eli Lilly - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024" report to their offering.

The head and neck cancer (HNC) market is one currently dominated by generic chemotherapies, with little competition from branded therapies. The market landscape is set to undergo substantial growth between 2014 and 2024. The main drivers of growth will be an increase in the diagnosed HNC population and the launch of multiple premium-priced metastatic therapies, led by the class of immuno-oncology products. Historically, cytotoxic chemotherapies have comprised the bulk of the HNC market. Little competition between targeted therapies currently exists in the HNC market, leaving an area of considerable opportunity for interested new comers.

The recent investment in HNC has seen a significant increase in research activity. The launch of new agents into the market and continued innovation in the developmental pipeline promises to produce a dynamic market over the forecast period.

Key Topics Covered:

  • Overview of HNC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
  • Annualized HNC therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the HNC therapeutics market.
  • Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Companies Mentioned:

  • Advaxis, Inc.
  • Amgen
  • AstraZeneca
  • Azanta A/S
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • CEL-SCI
  • Curis Pharmaceutical
  • Eli Lilly
  • F. Hoffman La-Roche
  • GlaxoSmithKline
  • Glycotope
  • Marsala Biotech
  • Merck & Co. (MSD)
  • Merck KGaA
  • Nordic Pharma
  • Oncolytics Biotech
  • Ono Pharmaceuticals
  • Pfizer
  • Pierre Fabre Medicament
  • Taiho Pharmaceutical

Report Structure:

1.1 List of Tables

1.2 List of Figures

2 Introduction

3 Disease Overview

4 Epidemiology

5 Current Treatment Options

6 Unmet Needs Assessment and Opportunity Analysis

7 R&D Strategies

8 Pipeline Assessment

9 Pipeline Valuation Analysis

10 Appendix

For more information visit http://www.researchandmarkets.com/research/8vgh52/opportunityanalyze

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Oncology Drugs